CymaBay Therapeutics, Inc.

NASDAQ (USD): CymaBay Therapeutics, Inc. (CBAY)

Last Price

32.229

Today's Change

+0.06 (0.18%)

Day's Change

32.18 - 32.259

Trading Volume

2,600,974

Overview

Market Cap

3 Billion

Shares Outstanding

114 Million

Avg Volume

3,567,160

Avg Price (50 Days)

25.00

Avg Price (200 Days)

16.23

PE Ratio

-34.66

EPS

-0.93

Earnings Announcement

14-Mar-2024

Previous Close

32.17

Open

32.19

Day's Range

32.18 - 32.26

Year Range

7.261 - 32.26

Trading Volume

2,901,644

Price Change Highlight

1 Day Change

0.19%

5 Day Change

0.28%

1 Month Change

43.50%

3 Month Change

68.74%

6 Month Change

144.17%

Ytd Change

35.93%

1 Year Change

311.10%

3 Year Change

563.17%

5 Year Change

187.00%

10 Year Change

258.11%

Max Change

258.11%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment